Showing 7291-7300 of 8881 results for "".
- BTL Launches Scholarship Program with Professional Basketball Player Andre Drummondhttps://practicaldermatology.com/news/btl-launches-scholarship-program-with-professional-basketball-player-andre-drummond/2460991/The BTL SCHOLAR DRAFT will grant five student athletes $15,000 each toward their college tuition. In addition, BTL has partnered with renowned, professional basketball player Andre Drummond to promote the BTL SCHOLAR DRAFT and award the winners. The program officially ki
- New International Recommendations for Treating Acne Scars with Energy-Based Deviceshttps://practicaldermatology.com/news/new-international-recommendations-for-treating-acne-scars-with-energy-based-devices/2460990/Energy-based devices are the first-line treatments for a variety of acne scars, according to new international consensus recommendations published in Lasers in Surgery and Medicine. For the first time
- National Rosacea Society Awards 2021 Research Grantshttps://practicaldermatology.com/news/national-rosacea-society-awards-2021-research-grants/2460988/The National Rosacea Society has awarded funding for two new studies in addition to continuing support for two ongoing studies as part of its
- With New Agreement, DermTech Melanoma Test Available Through DermatologistOnCallhttps://practicaldermatology.com/news/with-new-agreement-dermtech-melanoma-test-available-through-dermatologistoncall/2460987/The DermTech Melanoma Test is now available through DermatologistOnCall’s telemedicine platform. The DermTech Melanoma Test is a non-invasive test used to painlessly collect cellular material from the surface of a patient’s mole via t
- PsA Treatment Snapshot: Study Highlights Trends in PsA Treatment Since 2018https://practicaldermatology.com/news/psa-treatment-snapshot-study-highlights-trends-in-psa-treatment-since-2018/2460985/There’s been a significant increase in anti-IL17 and anti-phosphodiesterase-4 (anti-PDE4) medications being used as initial treatment for psoriatic arthritis (PsA) since 2018, which may reflect their inclusion as potential initial therapy in the American College of Rheumatology/National Pso
- Gryphon Investors to Acquire Revision Skincarehttps://practicaldermatology.com/news/gryphon-investors-to-acquire-revision-skincare/2460984/Gryphon Investors is set to acquire Revision Skincare and Goodier Cosmetics. The middle-market private equity firm has signed a definitive agreement to acquire the skincare company, with an anticipating closing date this year. Financial terms of the transaction were not disclosed.
- Skyrizi Improves PsA Signs and Symptomshttps://practicaldermatology.com/news/skyrizi-improves-psa-signs-and-symptoms/2460981/AbbVie’s risankizumab (SKYRIZI) showed greater improvements in psoriatic arthritis (PsA) signs and symptoms compared to treatment with placebo at week 24 in two Phase 3 clinical trials, according to research slated to be presented American College of Rheumatology (ACR) Convergence 2021.
- Study: Infection Rates in PsA Patients on Biologics Are Decreasinghttps://practicaldermatology.com/news/study-infection-rates-in-psa-patients-on-biologics-are-decreasing/2460979/Infection rates among people with psoriatic arthritis (PsA) taking biologics decreased from 2012 to 2017, according to new research presented at ACR Convergence, the American College of Rheumatology’s an
- RoC Skincare Marks the First National Retinol Dayhttps://practicaldermatology.com/news/roc-skincare-marks-the-first-national-retinol-day/2460977/Just as Americans set back their clocks this weekend, retinol can help turn back the clock on fine lines and wrinkles. That's the message from RoC® Skincare in honor of the first-ever National Retinol Day on Sunday. National Retinol Day has been registered for annual
- Sun Pharma’s WINLEVI for Acne Now Availablehttps://practicaldermatology.com/news/sun-pharmas-winlevi-for-acne-now-available/2460974/WINLEVI (clascoterone) cream 1% is now available the US, according to Sun Pharmaceutical Industries Limited. A first-in-class topical androgen receptor inhibitor, WINLEVI was approved by FDA in August 2020 for the topical treatment of acne vulgaris in patients 12 yea